DBV Tech Appoints Daniel Soland To Board; Didier Hoch Resigns

(RTTNews) - DBV Technologies (DBVT), a clinical-stage specialty biopharmaceutical company, Tuesday announced the appointment of Daniel Soland to its Board of Directors. Soland will join as an independent board member, and will be part of DBV's audit committee.

He most recently served as Senior Vice President and Chief Operating Officer of Viropharma, and currently serves on the Board of Tarsa Therapeutics.

Soland previously served as President of Chiron Vaccines, and helped engineer a turnaround that contributed to Chiron's acquisition by Novartis. Earlier, he was President and CEO of Epigenesis Pharmaceuticals.

Pierre-Henri Benhamou, Chairman & CEO said, "Our primary objective is to finish the development of Viaskin Peanut and bring it to the market. As DBV enters into this new chapter, Dan's commercial, marketing and operational experience will be an asset to DBV."

DBV also announced that Didier Hoch has resigned from his position as Board member in agreement with Bpifrance. Hoch was previously appointed in connection with Bpifrance Participations' investment in March 2012 during DBV's IPO on Euronext.

With recent capitalization changes, including a NASDAQ listing, BPI France's relative ownership interest in DBV has decreased, and Hoch's departure aims to reflect such change, the company noted.